These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19539578)

  • 41. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
    Yamamoto N; Mori R; Jacklin P; Osuga Y; Kawana K; Shibuya K; Taketani Y
    BJOG; 2012 Jan; 119(2):177-86. PubMed ID: 21794070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prophylactic HPV vaccination for women over 18 years of age.
    Adams M; Jasani B; Fiander A
    Vaccine; 2009 May; 27(25-26):3391-4. PubMed ID: 19200838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recommendations for cervical cancer prevention in Asia Pacific.
    Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
    Thomas TL
    Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
    Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
    Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination.
    Franco EL; Ferenczy A
    Future Oncol; 2007 Jun; 3(3):319-27. PubMed ID: 17547527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospects for cervical cancer prevention by human papillomavirus vaccination.
    Schiller JT; Lowy DR
    Cancer Res; 2006 Nov; 66(21):10229-32. PubMed ID: 17079437
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vaccination against HPV: indications for women and the impact on the cervical screening programme.
    Heideman DA; Snijders PJ; Berkhof J; Verheijen RH; Helmerhorst TJ; Meijer CJ
    BJOG; 2008 Jul; 115(8):938-46. PubMed ID: 18651878
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies.
    Canfell K; Shi JF; Lew JB; Walker R; Zhao FH; Simonella L; Chen JF; Legood R; Smith MA; Nickson C; Qiao YL
    Vaccine; 2011 Mar; 29(13):2487-94. PubMed ID: 21211586
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human papillomavirus vaccines: who will pay, who will receive, when to administer?
    Saslow D; Wheeler CM
    Ethn Dis; 2007; 17(2 Suppl 2):S2-8-13. PubMed ID: 17684807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural differences among cost-effectiveness models of human papillomavirus vaccines.
    Insinga RP; Dasbach EJ; Elbasha EH
    Expert Rev Vaccines; 2008 Sep; 7(7):895-913. PubMed ID: 18767941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of a potential vaccine for human papillomavirus.
    Sanders GD; Taira AV
    Emerg Infect Dis; 2003 Jan; 9(1):37-48. PubMed ID: 12533280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The current and future role of screening in the era of HPV vaccination.
    Myers E; Huh WK; Wright JD; Smith JS
    Gynecol Oncol; 2008 May; 109(2 Suppl):S31-9. PubMed ID: 18482556
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.
    Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F
    Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
    Dasbach EJ; Elbasha EH; Insinga RP
    Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human papillomavirus vaccine: a paradigm shift for pediatricians.
    Jenson HB
    Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of the human papillomavirus (HPV) vaccine in developing countries.
    Kling M; Zeichner JA
    Int J Dermatol; 2010 Apr; 49(4):377-9. PubMed ID: 20465688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness.
    Coupé VM; van Ginkel J; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
    Int J Cancer; 2009 Feb; 124(4):970-8. PubMed ID: 19035448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.